This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.
Head and Neck Cancer
Whitney Lewis, PharmD, BCOP
The University of Texas MD Anderson Cancer Center
Data on currently available immunotherapeutic agents for recurrent/metastatic head and neck squamous cell carcinoma point to a new standard of care with immune checkpoint inhibitors. Listen to the latest results comparing these inhibitors to chemotherapy, and the symptoms, workup, diagnosis, and management of a head and neck squamous cell carcinoma patient with hypophysitis.
These activities, certified for CME/CE/CPE credit, are jointly provided by
in collaboration with